SciHub
文献互助
期刊查询
一搜即达
科研导航
交流社区
登录
注册
发布
文献
求助
首页
我的求助
捐赠本站
清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!
yinlu
Lv7
4270 积分
2022-11-30 加入
最近求助
最近应助
互助留言
Immune checkpoint inhibitors and anti-vascular endothelial growth factor antibody/tyrosine kinase inhibitors with or without transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma (CHANCE2201): a target trial emulation study
15天前
已完结
Integrative single-cell analysis of human colorectal cancer reveals patient stratification with distinct immune evasion mechanisms
1个月前
已完结
Advances in multimodal imaging for diagnosis of pigmented ocular fundus lesions
1个月前
已完结
Adjuvant nivolumab plus chemotherapy versus placebo plus chemotherapy for stage III gastric or gastro-oesophageal junction cancer after gastrectomy with D2 or more extensive lymph-node dissection (ATTRACTION-5): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial
1个月前
已完结
肝细胞癌伴微血管侵犯诊断和治疗中国专家共识(2024版)
1个月前
已完结
IMbrave050: the first step towards adjuvant therapy in hepatocellular carcinoma
1个月前
已完结
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial
1个月前
已完结
Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial
1个月前
已完结
Adjuvant sintilimab in resected high-risk hepatocellular carcinoma: a randomized, controlled, phase 2 trial
1个月前
已完结
Safety and long‐term survival results of the addition of inotuzumab ozogamicin to the conditioning regimen of allogeneic stem cell transplantation: A single‐center phase 1,2 trial
1个月前
已完结
没有进行任何应助
已经找到了【积分已退回】
1个月前
已联系原文作者,下载到了【积分已退回】
4个月前
没有看到我的备注内容,下载的不符合要求
4个月前
已经下载【积分已退回】
5个月前
文章没有正式发表【积分已退回】
5个月前
不想要了【积分已退回】
10个月前
最近帖子
最近评论
没有发布任何帖子
没有发布任何评论